 Mary Bessesen
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Protective Devices | 6 | 2021 | 11 | 2.490 |
Why?
| | Infection Control | 8 | 2023 | 135 | 1.520 |
Why?
| | Health Personnel | 10 | 2021 | 574 | 1.480 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 191 | 1.400 |
Why?
| | Staphylococcal Infections | 5 | 2016 | 336 | 1.250 |
Why?
| | Respiratory Tract Infections | 5 | 2021 | 319 | 1.180 |
Why?
| | Bacteremia | 5 | 2020 | 160 | 1.080 |
Why?
| | Cross Infection | 6 | 2023 | 197 | 1.070 |
Why?
| | Equipment Reuse | 2 | 2015 | 11 | 1.000 |
Why?
| | Disinfection | 2 | 2015 | 106 | 0.910 |
Why?
| | Masks | 4 | 2021 | 46 | 0.890 |
Why?
| | Carrier State | 3 | 2016 | 54 | 0.750 |
Why?
| | Antimicrobial Stewardship | 1 | 2023 | 94 | 0.740 |
Why?
| | Veterans | 3 | 2020 | 1248 | 0.700 |
Why?
| | Diabetic Foot | 1 | 2020 | 22 | 0.680 |
Why?
| | Rifampin | 1 | 2020 | 68 | 0.660 |
Why?
| | Osteomyelitis | 1 | 2020 | 101 | 0.610 |
Why?
| | Influenza, Human | 5 | 2022 | 546 | 0.600 |
Why?
| | Nose | 2 | 2015 | 55 | 0.580 |
Why?
| | Sepsis | 1 | 2023 | 509 | 0.570 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 179 | 0.510 |
Why?
| | Anti-HIV Agents | 2 | 2018 | 666 | 0.490 |
Why?
| | HIV Infections | 3 | 2018 | 2469 | 0.440 |
Why?
| | Medication Adherence | 1 | 2018 | 536 | 0.430 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 1999 | 116 | 0.400 |
Why?
| | Polymers | 1 | 2015 | 448 | 0.390 |
Why?
| | Occupational Exposure | 2 | 2019 | 255 | 0.380 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 256 | 0.370 |
Why?
| | Catheters, Indwelling | 1 | 2010 | 79 | 0.340 |
Why?
| | Osteoporosis | 1 | 2012 | 226 | 0.340 |
Why?
| | Catheter-Related Infections | 1 | 2010 | 62 | 0.340 |
Why?
| | Delivery of Health Care | 6 | 2022 | 833 | 0.330 |
Why?
| | Catheterization, Central Venous | 1 | 2010 | 83 | 0.320 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 100 | 0.300 |
Why?
| | Microbiota | 1 | 2015 | 647 | 0.300 |
Why?
| | Anti-Bacterial Agents | 5 | 2023 | 1477 | 0.290 |
Why?
| | Humans | 37 | 2023 | 114623 | 0.280 |
Why?
| | Influenza Vaccines | 2 | 2022 | 497 | 0.280 |
Why?
| | Elastomers | 2 | 2015 | 24 | 0.250 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1999 | 217 | 0.230 |
Why?
| | Mycobacterium avium | 1 | 2004 | 21 | 0.230 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 17 | 0.230 |
Why?
| | Molecular Typing | 1 | 2013 | 18 | 0.220 |
Why?
| | Polymerase Chain Reaction | 3 | 2015 | 993 | 0.220 |
Why?
| | Mycobacterium avium-intracellulare Infection | 2 | 2004 | 63 | 0.220 |
Why?
| | Peritonitis | 1 | 2004 | 77 | 0.220 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2013 | 63 | 0.210 |
Why?
| | Clostridium Infections | 1 | 2023 | 56 | 0.210 |
Why?
| | Adult | 12 | 2023 | 30528 | 0.200 |
Why?
| | Feasibility Studies | 2 | 2015 | 739 | 0.200 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 5 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 1 | 2022 | 54 | 0.190 |
Why?
| | Male | 16 | 2020 | 55554 | 0.190 |
Why?
| | Escherichia coli | 2 | 2013 | 720 | 0.190 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 139 | 0.180 |
Why?
| | Viruses | 1 | 2021 | 94 | 0.170 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 21 | 0.170 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 385 | 0.170 |
Why?
| | Placebos | 1 | 2020 | 197 | 0.170 |
Why?
| | Attitude | 1 | 2021 | 229 | 0.170 |
Why?
| | Hepatitis B, Chronic | 1 | 1999 | 18 | 0.160 |
Why?
| | Foot | 1 | 2020 | 103 | 0.160 |
Why?
| | Lamivudine | 1 | 1999 | 59 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 96 | 0.160 |
Why?
| | Middle Aged | 9 | 2020 | 26719 | 0.160 |
Why?
| | Financing, Government | 1 | 1999 | 40 | 0.160 |
Why?
| | Female | 12 | 2020 | 59466 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2020 | 222 | 0.150 |
Why?
| | Outpatients | 1 | 2021 | 326 | 0.150 |
Why?
| | Mandatory Programs | 1 | 2018 | 15 | 0.150 |
Why?
| | Nasal Cavity | 2 | 2016 | 47 | 0.150 |
Why?
| | Sterilization | 1 | 2017 | 11 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2020 | 12542 | 0.130 |
Why?
| | Vaccination | 3 | 2021 | 1204 | 0.130 |
Why?
| | Antibiosis | 1 | 2015 | 7 | 0.130 |
Why?
| | Streptococcus mitis | 1 | 2015 | 8 | 0.130 |
Why?
| | Lactobacillus | 1 | 2015 | 24 | 0.130 |
Why?
| | Double-Blind Method | 1 | 2020 | 1660 | 0.130 |
Why?
| | Nasal Mucosa | 1 | 2016 | 93 | 0.130 |
Why?
| | Catalase | 1 | 2015 | 118 | 0.120 |
Why?
| | Pyrimethamine | 1 | 1995 | 1 | 0.120 |
Why?
| | Sulfadoxine | 1 | 1995 | 4 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 126 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2020 | 9084 | 0.120 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 55 | 0.120 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 24 | 0.120 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 723 | 0.120 |
Why?
| | Equipment Contamination | 1 | 2015 | 54 | 0.120 |
Why?
| | Risk Factors | 4 | 2021 | 8628 | 0.120 |
Why?
| | Occupational Diseases | 1 | 2016 | 128 | 0.120 |
Why?
| | Reference Standards | 1 | 2015 | 159 | 0.120 |
Why?
| | Efficiency, Organizational | 2 | 2018 | 125 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 544 | 0.120 |
Why?
| | Aged | 3 | 2020 | 19061 | 0.120 |
Why?
| | Medical Errors | 1 | 2015 | 85 | 0.110 |
Why?
| | Prospective Studies | 3 | 2020 | 6217 | 0.110 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 159 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 194 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4411 | 0.110 |
Why?
| | HIV-1 | 1 | 1999 | 768 | 0.110 |
Why?
| | Cohort Studies | 3 | 2020 | 4894 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 485 | 0.110 |
Why?
| | Biomarkers | 1 | 2023 | 3408 | 0.110 |
Why?
| | Mycobacterium Infections | 1 | 1993 | 61 | 0.110 |
Why?
| | Prevalence | 2 | 2013 | 2249 | 0.100 |
Why?
| | Bone Density Conservation Agents | 1 | 2012 | 62 | 0.100 |
Why?
| | Risk Assessment | 2 | 2016 | 2967 | 0.100 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 56 | 0.100 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 560 | 0.090 |
Why?
| | Incidence | 2 | 2019 | 2311 | 0.090 |
Why?
| | Ergonomics | 1 | 2010 | 23 | 0.090 |
Why?
| | United States | 4 | 2018 | 12176 | 0.080 |
Why?
| | Listeria monocytogenes | 1 | 1990 | 111 | 0.080 |
Why?
| | Metagenome | 1 | 2010 | 122 | 0.080 |
Why?
| | Hospitalization | 2 | 2015 | 1749 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6344 | 0.080 |
Why?
| | Molecular Epidemiology | 2 | 2013 | 62 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 951 | 0.070 |
Why?
| | Cytosine | 1 | 2005 | 44 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 90 | 0.060 |
Why?
| | Young Adult | 1 | 2020 | 10455 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2005 | 87 | 0.060 |
Why?
| | Adolescent | 3 | 2020 | 17831 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2019 | 478 | 0.060 |
Why?
| | Immunocompetence | 1 | 2004 | 40 | 0.060 |
Why?
| | Fluoroquinolones | 1 | 2013 | 41 | 0.050 |
Why?
| | beta-Lactams | 1 | 2013 | 27 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 371 | 0.050 |
Why?
| | Inpatients | 2 | 2020 | 380 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2022 | 37 | 0.050 |
Why?
| | Virulence Factors | 1 | 2013 | 139 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 40 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 162 | 0.050 |
Why?
| | Nurses | 1 | 2023 | 145 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2023 | 582 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2005 | 645 | 0.040 |
Why?
| | Hepatitis B e Antigens | 1 | 1999 | 2 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 822 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 158 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 520 | 0.040 |
Why?
| | Genotype | 1 | 2013 | 1760 | 0.040 |
Why?
| | Treatment Failure | 1 | 1999 | 331 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 40 | 0.040 |
Why?
| | Surgical Instruments | 1 | 2017 | 47 | 0.030 |
Why?
| | Hospital Costs | 1 | 2017 | 104 | 0.030 |
Why?
| | Operating Rooms | 1 | 2017 | 86 | 0.030 |
Why?
| | Recurrence | 1 | 1999 | 935 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2537 | 0.030 |
Why?
| | Immunization Programs | 1 | 2018 | 205 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2015 | 7 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 442 | 0.030 |
Why?
| | Pentamidine | 1 | 1995 | 3 | 0.030 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.030 |
Why?
| | Personal Protective Equipment | 1 | 2015 | 49 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 334 | 0.030 |
Why?
| | Zidovudine | 1 | 1995 | 77 | 0.030 |
Why?
| | Workplace | 1 | 2016 | 220 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1995 | 641 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 287 | 0.030 |
Why?
| | Occupational Health | 1 | 2015 | 165 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2015 | 372 | 0.020 |
Why?
| | Digestive System | 1 | 1991 | 27 | 0.020 |
Why?
| | Listeria | 1 | 1990 | 6 | 0.020 |
Why?
| | Patients' Rooms | 1 | 2010 | 13 | 0.020 |
Why?
| | Facility Design and Construction | 1 | 2010 | 11 | 0.020 |
Why?
| | Manikins | 1 | 2010 | 24 | 0.020 |
Why?
| | Diarrhea | 1 | 1991 | 171 | 0.020 |
Why?
| | Time and Motion Studies | 1 | 2010 | 20 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 167 | 0.020 |
Why?
| | Hand Disinfection | 1 | 2010 | 22 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 40 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 79 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 111 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 144 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1995 | 333 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6112 | 0.020 |
Why?
| | Feedback | 1 | 2010 | 144 | 0.020 |
Why?
| | Health | 1 | 2010 | 74 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 71 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 83 | 0.020 |
Why?
| | Workload | 1 | 2010 | 132 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 141 | 0.020 |
Why?
| | Species Specificity | 1 | 1990 | 542 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 508 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 275 | 0.020 |
Why?
| | Cues | 1 | 2010 | 300 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 311 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 141 | 0.020 |
Why?
| | Attention | 1 | 2010 | 393 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 349 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 494 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2010 | 617 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1990 | 1691 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2785 | 0.020 |
Why?
| | Simplexvirus | 1 | 2005 | 80 | 0.020 |
Why?
| | Child | 2 | 2021 | 18404 | 0.020 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 99 | 0.010 |
Why?
| | Bacteria | 1 | 1990 | 725 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 239 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2387 | 0.010 |
Why?
| | Life Tables | 1 | 1995 | 17 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 257 | 0.010 |
Why?
| | Australia | 1 | 1995 | 206 | 0.010 |
Why?
| | Mycobacterium avium Complex | 1 | 1995 | 92 | 0.010 |
Why?
| | Europe | 1 | 1995 | 334 | 0.010 |
Why?
| | North America | 1 | 1995 | 256 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 1644 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3003 | 0.000 |
Why?
|
|
Bessesen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|